IncellDx, Inc. is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers.
Recognizing every cell tells a story we are dedicated to revolutionizing healthcare one cell at a time. Combining proprietary molecular diagnostics with cellular analysis, we offer diagnostic, prognostic and therapeutic clinical information for physicians to make more informed clinical decisions.
HPV OncoTect 3Dx™
More than 450,000 new cases of cervical cancer are diagnosed each year. Our CE-IVD HPV OncoTect 3Dx™ for in vitro diagnostics is a unique quantative cell based assay that measures both mRNA E6 and E7.
IncellDx’s Single Cell Immuno-Oncology/PD-L1 Technology being used by Sirona Dx
Sirona Dx Launches Novel Urine-Based Bladder Cancer Assay with PD-L1 Quantification Based on IncellDx’s Single Cell Immuno-Oncology/PD-L1 Technology
IncellDx published in American Journal of Clinical Pathology
Concordance of PD-L1 Expression Detection in Non–Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC)
IncellDx Releases CE-IVD Quantitative Single Cell PD-L1 OncoTect iO® Assay
IncellDx, Inc. announces the release of their CE marked OncoTect iO® Lung Kit today, entering the immunotherapeutic diagnostic market in Europe and other countries that accept the CE- mark.